We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ARCA Biopharma Inc (ABIO) USD0.001

Sell:$3.38 Buy:$3.57 Change: $0.02 (0.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.38
Buy:$3.57
Change: $0.02 (0.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.38
Buy:$3.57
Change: $0.02 (0.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Contact details

Address:
10170 Church Ranch Way, Suite 100
WESTMINSTER
80021
United States
Telephone:
+1 (720) 9402200
Website:
https://arcabio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ABIO
ISIN:
US00211Y5069
Market cap:
$51.50 million
Shares in issue:
14.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Keuer
    President, Principal Executive Officer, Chief Operating Officer
  • C. Jeffrey Dekker
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.